AIM: To review previous studies (the last 6 years) about the Helicobacter pylori (H. pylori) antibiotic resistance in order to evaluate the trend in antibiotic resistance. METHODS: In this study, the PubMed, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014. RESULTS: On the whole rates of H. pylori antibiotic resistance were 47.22% (30.5%-75.02%) for metronidazole, 19.74% (5.46%-30.8%) for clarithromycin, 18.94% (14.19%-25.28%) for levofloxacin, and 14.67% (2%-40.87%) for amoxicillin, 11.70% (0%-50%) for tetracycline, 11.5% (0%-23%) for furazolidon and 6.75% (1%-12.45%) for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levofloxacin resistance was higher in North America and Asian, respectively. CONCLUSION: The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide H. pylori antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of H. pylori infections.
AIM: To review previous studies (the last 6 years) about the Helicobacter pylori (H. pylori) antibiotic resistance in order to evaluate the trend in antibiotic resistance. METHODS: In this study, the PubMed, MEDLINE, Science Direct, Google Scholar and Scielo manuscripts were reviewed from 2009 to 2014. RESULTS: On the whole rates of H. pylori antibiotic resistance were 47.22% (30.5%-75.02%) for metronidazole, 19.74% (5.46%-30.8%) for clarithromycin, 18.94% (14.19%-25.28%) for levofloxacin, and 14.67% (2%-40.87%) for amoxicillin, 11.70% (0%-50%) for tetracycline, 11.5% (0%-23%) for furazolidon and 6.75% (1%-12.45%) for rifabutin. The frequency of tetracycline, metronidazole and amoxicillin resistance was higher in Africa, while clarithromycin and levofloxacin resistance was higher in North America and Asian, respectively. CONCLUSION: The most sensitive drug is rifabutin and the lowest sensitive drug is metronidazole in the world. The worldwide H. pylori antibiotic resistance to clarithromycin and levofloxacin has increased during the last 6 years. The present systematic review show alarming results and a novel plan is needed for eradication therapy of H. pylori infections.
Authors: P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers Journal: Gut Date: 2006-12-14 Impact factor: 23.059
Authors: V Y Miendje Deyi; V Y Miendje Deyi; P Bontems; J Vanderpas; E De Koster; R Ntounda; C Van den Borre; S Cadranel; A Burette Journal: J Clin Microbiol Date: 2011-03-30 Impact factor: 5.948
Authors: Ousman Secka; Douglas E Berg; Martin Antonio; Tumani Corrah; Mary Tapgun; Robert Walton; Vivat Thomas; Juan J Galano; Javier Sancho; Richard A Adegbola; Julian E Thomas Journal: Antimicrob Agents Chemother Date: 2012-12-21 Impact factor: 5.191
Authors: A Karvelas; B Martinez-Gonzalez; V P Papadopoulos; M Panopoulou; D Sgouras; K Mimidis Journal: Hippokratia Date: 2021 Apr-Jun Impact factor: 0.522
Authors: Anthony Mannion; JoAnn Dzink-Fox; Zeli Shen; M Blanca Piazuelo; Keith T Wilson; Pelayo Correa; Richard M Peek; M Constanza Camargo; James G Fox Journal: J Clin Microbiol Date: 2021-04-20 Impact factor: 5.948
Authors: Ha Van Thieu; Nguyen Minh Duc; Bui Thi Dung Nghi; Ngo Van Bach; Ha Huy Khoi; Vo Ngoc Thuy Tien; Mai Tan Lien Bang; Tang Le Chau Ngoc Journal: Med Arch Date: 2021-04
Authors: Jewel Ju Ea Kim; Ildikó Kocsmár; György Miklós Buzás; Ildikó Szirtes; Orsolya Rusz; Csaba Diczházi; Attila Szijártó; István Hritz; Zsuzsa Schaff; András Kiss; Éva Kocsmár; Gábor Lotz Journal: Pathol Oncol Res Date: 2021-06-29 Impact factor: 3.201